[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Recruiting Phase 2 Interventional Study
Acute Cellular Graft Rejection Cardiac Sarcoidosis Myocarditis Due to Drug
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Diagnostic
Participants needed
69 (estimated)
Sponsor
John O. Prior · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains c…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * signed written informed consent * male or female * age ≥ 18 years * patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I) * SOC clinical follow-up at the cardiology department in CHUV. Exclusion Criteria…
Contacts

John O Prior, MD, PhD

+44795568702

john.prior@chuv.ch

CONTACT

Christel Kamani, MD

CONTACT